By Maggie Fick and Jacob Gronholt-Pedersen LONDON/COPENHAGEN (Reuters) -Novo Nordisk will target launches of its mega popular obesity shot Wegovy in markets where it already has strong sales of its…
INDIANAPOLIS, IN – Pharmaceutical giant Eli Lilly announced the availability of its new obesity treatment, Zepbound, in U.S. pharmacies. The drug, priced at $550 monthly for uninsured patients, is half…
By Bhanvi Satija and Amruta Khandekar (Reuters) – Retail flows into Eli Lilly spiked to a more than two-year high in November, as small investors rushed to buy the stock…
By Maggie Fick and Bhanvi Satija (Reuters) – Novo Nordisk and Eli Lilly both expect juggernaut sales for their diabetes and weight-loss drugs to extend into coming years – limited…
(Reuters) – Eli Lilly and Co said on Thursday it will acquire all the shares of Sigilon Therapeutics that it did not own to gain access to experimental cell therapies…
By Deena Beasley (Reuters) -Eli Lilly on Monday said a mid-stage trial of its next-generation obesity drug candidate “triple G” showed that it led to weight loss of up to…
By Deena Beasley (Reuters) -In a mid-stage trial, the highest dose of Eli Lilly’s experimental pill orforglipron led to 14.7% weight loss after 36 weeks for people who were obese…
(Reuters) – Eli Lilly and Co said on Monday it will invest an additional $1.6 billion at its two new manufacturing sites in Indiana, United States to support the manufacturing…
(Removes reference to Ricks’ comment on apology from Lilly in paragraph 3) (Reuters) -Eli Lilly & Co Chief Executive Officer Dave Ricks said on Wednesday that the recent imposter Twitter…
By Natalie Grover LONDON (Reuters) – The results of a key Alzheimer’s drug trial on Wednesday have reignited decades-old hopes that targeting a particular protein helps arrest the progression of…